Galapagos reports CF data, provides update on AbbVie partnership

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported that GLPG2737 failed to significantly improve lung function in the Phase II PELICAN trial to treat cystic fibrosis. The company also said partner AbbVie Inc. (NYSE:ABBV) has scrapped plans for a second trial of a triple combination CF therapy.

The double-blind, German PELICAN trial enrolled 22 CF patients homozygous for the F508del mutation who were on stable treatment with Orkambi ivacaftor/lumacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) for at least 12 weeks prior to receiving GLPG2737. Patients were required to continue treatment with Orkambi for the duration of the trial...